Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 8.5.2023 | EN | Official Journal of the European Union | C 164/39 |

---

Judgment of the General Court of 15 March 2023 — Novartis v EUIPO — AstraZeneca (BREZTREV)

(Case T-174/22) [(1)](#ntr1-C_2023164EN.01003901-E0001)

(EU trade mark - Opposition proceedings - Application for the EU word mark BREZTREV - Earlier EU word marks ONBREZ, DAYBREZ, BREZILIZER and BREEZHALER - No likelihood of confusion - Article 8(1)(b) of Regulation (EU) 2017/1001)

(2023/C 164/53)

Language of the case: English

Parties

Applicant: Novartis AG (Basle, Switzerland) (represented by: A. Nordemann-Schiffel, lawyer)

Defendant: European Union Intellectual Property Office (represented by: N. Lamsters and T. Frydendahl, acting as Agents)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: AstraZeneca AB (Södertälje, Sweden) (represented by: C. Tenkhoff and T. Herzog, lawyers)

Re:

By its action under Article 263 TFEU, the applicant seeks the annulment of the decision of the Second Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 21 January 2022 (Case R 738/2021-2).

Operative part of the judgment

The Court:

|  |  |
| --- | --- |
| 1. | Dismisses the action; |

|  |  |
| --- | --- |
| 2. | Orders Novartis AG to pay the costs. |

---

---

[Top](#document1)